Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pertuzumab
Find trials that include:  Any drugs shown
Results 1-17 of 17 for your search:
Start Over
Gemcitabine Hydrochloride, Trastuzumab, and Pertuzumab in Treating Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17656, NCI-2014-01935, 280513, 14.01.0062, ML28939, NCT02139358
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with HER2-Positive Stage II-IV Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 12147, NCI-2012-02371, 105932, 109681, 119638, NCT01730833
Paclitaxel, Trastuzumab, and Pertuzumab before Surgery in Treating Patients with Inflammatory Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-497, NCI-2013-01110, ML28193, NCT01796197
Pertuzumab and Trastuzumab with Combination Chemotherapy before Surgery in Treating Patients with Stage I-III HER2 Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: 1305012136, NCI-2015-02018, ML28772, NCT01855828
Eribulin Mesylate, Trastuzumab, and Pertuzumab in Treating Patients with HER2-Positive Breast Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-163, NCI-2013-01826, 707389, 688097, NCT01912963
Stereotactic Radiosurgery Followed by HER2 Directed Therapy in Treating Patients with HER2 Positive Breast Cancer with Newly Diagnosed Brain Metastasis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1345GCC, NCI-2015-02007, NCT01924351
FDG-PET in Predicting Treatment Response in Patients with Newly Diagnosed Stage II-IV Breast Cancer Receiving Pertuzumab and Trastuzumab Prior to Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 026, NCI-2014-01543, NCI-2014-00245, NA_00080994, NCT01937117
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ML28897, NCI-2014-01811, NCT02091141
Trastuzumab Emtansine and Pertuzumab before Surgery in Treating Patients with HER2-Positive Stage II-III Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-409, NCI-2015-00454, NCT02326974
Carboplatin and Paclitaxel with Pertuzumab and Trastuzumab or Bevacizumab in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCI 14-67, NCI-2015-02066, NCT02436993
An Extension Study of Trastuzuma Emtansine in Patients Previously Treated With Trastuzuma Emtansine
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TDM4529g, NCI-2009-01154, BO25430, NCT00781612
Taselisib and Anti-HER2 Therapy in Treating Patients with Advanced HER2+ Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-024, NCI-2015-00627, ML29407, NCT02390427
Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29831, NCI-2015-02225, 2015-002113-29, NCT02605915
Pertuzumab and Trastuzumab in Treating Patients with HER2 Positive Breast Cancer with Untreated Brain Metastasis
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00061309, NCI-2016-00827, NCT02598427
Trastuzumab, Pertuzumab, and Lapatinib Ditosylate in Measuring Kinome Response in Patients with HER2+ Breast Cancer Undergoing Surgery
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: LCCC 1214, NCI-2014-01407, NCI-2014-00972, 13-1826, NCT01875666
Start Over